Switch to Maraviroc + Raltegravir

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified July 2013 by University of Maryland
Information provided by (Responsible Party):
David Riedel, University of Maryland
ClinicalTrials.gov Identifier:
First received: June 27, 2013
Last updated: July 8, 2013
Last verified: July 2013

June 27, 2013
July 8, 2013
July 2013
July 2016   (final data collection date for primary outcome measure)
Proportion of patients virologically suppressed (HIV RNA <50 copies/ml) at 48weeks. [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01896921 on ClinicalTrials.gov Archive Site
  • Mean percent change in total cholesterol, LDL, and HDL [ Time Frame: 48 and 96 weeks ] [ Designated as safety issue: Yes ]
  • Number of participants with adverse events [ Time Frame: 48 and 96 weeks ] [ Designated as safety issue: Yes ]
  • proportion of patients who are virologically suppressed (HIV RNA < 50 copies/ml) [ Time Frame: 96 weeks ] [ Designated as safety issue: No ]
Same as current
telomerase activity and telomere length. [ Time Frame: 48 and 96 weeks ] [ Designated as safety issue: No ]
Same as current
Switch to Maraviroc + Raltegravir
Switch to Maraviroc and Raltegravir Combination Therapy (a Triple Class-Sparing Regimen) for the Treatment of HIV-1-Infected Patients on Suppressive Antiretroviral Regimens

This clinical study proposes to evaluate the combination of maraviroc with raltegravir in antiretroviral-experienced patients to document the efficacy, safety, and tolerability of this combination in order to provide clinicians with a treatment regimen that minimizes the risk of metabolic complications by avoidance of NRTI/NNRTIs and PIs. The development of an alternative ART regimen which lessens the risk of metabolic complications could improve long-term adherence and reduce the risk of certain co-morbidities associated with long-term ART use. If this new combination is found to be as efficacious as the standard regimen with enhanced tolerability and improved metabolic effects, there is great potential for altering the current practice of HIV medicine.

Not Provided
Phase 3
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Drug: Switch to Maraviroc + Raltegravir
Change HIV-infected patients on stable, suppressed ART regimens for at least 1 year to experimental regimen of Maraviroc + Raltegravir
Experimental: Maraviroc + Raltegravir
Maraviroc 300 mg tablet twice a day, Raltegravir 400 mg tablet twice a day
Intervention: Drug: Switch to Maraviroc + Raltegravir
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Not yet recruiting
July 2016
July 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • HIV-1 infection
  • Age between 18 and 75 years
  • CD4 count nadir ≥ 350 cells/mm3
  • HIV RNA ≤ 50 copies/ml for ≥ 12 months while taking any ART regimen

    o One virologic blip ≤ 400 copies/ml permissible within the 12 months

  • CCR5 tropic virus as defined by:

    • trofile/tropism testing if available, OR
    • DNA trofile if no trofile/tropism test available and CD4 nadir 350-499 cells/mm3, OR
    • CD4 nadir ≥ 500 cells/mm3

Exclusion Criteria:

  • Age < 18 or > 75 years
  • CD4 count nadir < 350 cells/mm3
  • Dual/mixed or X4 tropic virus if tested prior to viral suppression or if performed by DNA trofile testing at any time
  • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5 times the upper limits of normal
  • Women who:

    • are currently pregnant or breastfeeding
    • are of child-bearing age and do not agree to remain abstinent or use (or have their partner use) an acceptable method of birth control throughout the study. Acceptable method of birth control is defined as intrauterine device (IUD), diaphragm with spermicide, contraceptive sponge, condom, vasectomy.
  • History of any malignancy except non-melanoma skin cancer
  • Concomitant use of drugs known to impact or be impacted in terms of pharmacokinetics or drug-drug interactions with either raltegravir or maraviroc. This includes:

    • Inducers of UGT1A1 (such as rifampin, phenytoin, phenobarbital rifabutin, St. John's wort)
    • CYP3A inhibitors (such as ketoconazole, itraconazole, clarithromycin, nefazodone, and telithromycin)
    • CYP3A inducers (such as rifampin, carbamazepine, phenobarbital and phenytoin)
  • Subject requires or is anticipated to require any of the prohibited medications noted in the protocol
  • Enrollment in an experimental protocol having received investigational agents (antiretroviral or non-antiretroviral) within 30 days of study enrollment
  • Chronic active hepatitis B infection as defined by presence of HBsAg
  • Subject has a history or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might interfere with the patient's participation for the full duration of the study, such that it is not in the best interest of the patient to participate.
  • Subject is unlikely to adhere to the study procedures, keep appointments, or is planning to relocate during the study.
18 Years to 75 Years
Contact: Gregg Brogden 410-706-1660 gbrogden@ihv.umaryland.edu
United States
David Riedel, University of Maryland
University of Maryland
Not Provided
Not Provided
University of Maryland
July 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP